Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a clinical-stage precision medicine company that is transforming the drug discovery process by utilizing their Dynamo platform to target previously "intractable" protein targets. With short interest representing 24.51% of the public float, there is potential for a significant short squeeze, especially with upcoming data updates expected by the end of 2026 for their lead candidate, zovegalisib. The company's strong financial position and expanding pipeline, with key data catalysts expected into 2029, support a positive outlook for Relay Therapeutics' potential for future success in precision oncology and genetic diseases.

Bears say

Relay Therapeutics is a promising precision medicine company, but our financial analyst has a negative outlook on their stock due to several reasons. The company has a high operating expense of $91.2M in the second quarter of 2026, and they are heavily reliant on their pipeline of drug candidates, which may not be successful in clinical trials. Additionally, the analyst believes that competition for their lead drug candidate, zovegalisib, is minimal. Also, there is concern about the toxicity and limited efficacy of their drug, alpelisib, in treating a specific disease, vascular anomalies.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.